These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37438091)

  • 21. Assessment of the physical compatibility of injectable enrofloxacin with commonly used intravenous fluids and drugs during simulated Y-port administration.
    Aghili A; Thomovsky EJ; Johnson PA; Brooks AC; Pierce TJ; Gochenauer AE
    Am J Vet Res; 2021 May; 82(5):358-366. PubMed ID: 33904804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
    Meyer K; Santarossa M; Danziger LH; Wenzler E
    Hosp Pharm; 2017 Mar; 52(3):221-228. PubMed ID: 28439137
    [No Abstract]   [Full Text] [Related]  

  • 23. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stability of
    Friciu MM; Monfort A; Dubé PA; Leclair G
    Can J Hosp Pharm; 2021; 74(4):344-349. PubMed ID: 34602622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
    De Basagoiti A; Katsumiti A; Abascal S; Bustinza A; López-Giménez LR; Pascual P; De Miguel M; Campino A
    Eur J Pediatr; 2021 Apr; 180(4):1169-1176. PubMed ID: 33128625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compatibility of doripenem with other drugs during simulated Y-site administration.
    Brammer MK; Chan P; Heatherly K; Trusley C; Kupiec TC; Trissel LA; Psathas PA; Gilmor T; Schaufelberger D
    Am J Health Syst Pharm; 2008 Jul; 65(13):1261-5. PubMed ID: 18574017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Droperidol stability in intravenous admixtures.
    Ray JB; Newton DW; Nye MT; Leet WA
    Am J Hosp Pharm; 1983 Jan; 40(1):94-7. PubMed ID: 6823997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection.
    Wu G; Powers D; Yeung S; Chen F
    Int J Pharm Compd; 2018; 22(1):76-85. PubMed ID: 29385388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs.
    Hammond S; Wignell A; Cooling P; Barrett DA; Davies P
    Intensive Care Med Exp; 2020 Jun; 8(1):25. PubMed ID: 32577941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
    Holyk AA; Lindner AH; Lindner SE; Shippert BW
    Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration.
    Foushee JA; Fox LM; Gormley LR; Lineberger MS
    Am J Health Syst Pharm; 2015 Mar; 72(6):483-6. PubMed ID: 25736944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
    Kenneally AM; Agbana P; Gardner B; Bae Y; Mitchell T; Beckman EJ
    Am J Health Syst Pharm; 2023 Jan; 80(3):164-170. PubMed ID: 36282720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
    Foushee JA; Meredith P; Fox LM; Wilder AG
    Am J Health Syst Pharm; 2020 Jul; 77(14):1144-1148. PubMed ID: 32537625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of ranitidine hydrochloride at dilute concentration in intravenous infusion fluids at room temperature.
    Galante LJ; Stewart JT; Warren FW; Johnson SM; Duncan R
    Am J Hosp Pharm; 1990 Jul; 47(7):1580-4. PubMed ID: 2368751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC; Trusley C; Ben M; Trissel LA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1735-59. PubMed ID: 18769000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
    Ross EL; Salinas A; Petty K; Her C; Carpenter JF
    Am J Health Syst Pharm; 2020 Nov; 77(23):1980-1985. PubMed ID: 32974650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stability study of azlocillin sodium in glass bottles and PVC bags containing intravenous admixtures.
    Puiggròs Boldú S; Pujol Cubells M; Girona Brumós V; Prat Aixelà J; Muñoz Juncosa M
    Boll Chim Farm; 1995 Sep; 134(8):467-71. PubMed ID: 7576447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.